Drug intelligence / Profile preview

HL-1186

Development stage: Phase 3
Lead developer: Shanghai Yidian Pharmaceutical Technology Development
Modality: Small Molecules
Administration: Oral

Overview

HL-1186 is an investigational oral drug currently being evaluated in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics in healthy participants. The study is a single-center, randomized, double-blind, placebo-controlled trial involving both single and multiple oral doses of HL-1186. As of now, there is no publicly available information regarding its mechanism of action, therapeutic class, or primary indication beyond the fact that it is being tested in healthy volunteers.

Beyond the preview

Go deeper on HL-1186.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL-1186.

Explore the full profile